3 Stocks Heading Out of the Dow Doghouse in 2014
The Dogs of the Dow strategy looks at the highest-yielding stocks in the Dow Jones Industrials. Find out which stocks will probably drop out of the list in 2014.
Two Small Alternatives to Johnson & Johnson
Bigger is not always better. This appears to be the case with Church & Dwight and Prestige Brands, two relatively small companies succeeding in an industry dominated by behemoths.
3 Budding Drug Superstars in This Big Pharma's Future
Can Bristol-Myers Squibb keep its amazing growth in 2013 going strong in the future? It'll rely on ballyhooed drugs like these to discover its future growth.
Let the Hep C Drug War Begin
The approval of Gilead's Sovaldi sets the drug up to compete with Johnson & Johnson's Olysio, leaving Vertex Pharmaceuticals' and Merck's first-generation hepatitis C drugs in their wake. The fight may be short-lived, though, as patients wait for all-oral combinations from Gilead and AbbVie.
What Johnson & Johnson Shareholders Have to Look Forward To
A look at what may be lying ahead in 2014 for Johnson & Johnson and its shareholders.